Vasicinona

Otros Nombres

(3R)-2,3-Dihydro-3-hydroxypyrrolo[2,1-b]quinazolin-9(1H)-one(3R)-2,3-Dihydro-3β-hydroxypyrrolo[2,1-b]quinazoline-9(1H)-one(3S)-2,3-dihydro-3-hydroxy-pyrrolo[2,1-b]quinazolin-9(1H)-one(3S)-2,3-Dihydro-3-hydroxypyrrolo[2,1-b]quinazolin-9(1H)-one(3S)-3-HYDROXY-1H,2H,3H,9H-PYRROLO[2,1-B]QUINAZOLIN-9-ONE(3S)-3-hydroxy-2,3-dihydro-1H-pyrrolo[2,1-b]quinazolin-9-one(3S)-3-Hydroxy-2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-one2,3-dihydro-3(S)-hydroxypyrrolo[2,1-b]quinazolin-9(1H)-one2,3-Dihydro-3-hydroxypyrrolo[2,1-b]quinazolin-9(1H)-onel-VasicinonePyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-hydroxy-, (3S)-S(-)-Vasicinone

Sinopsis

Vasicinone: A Comprehensive Reference

1. Identity and Chemical Characterization

1.1 Nomenclature and Chemical Identity

Vasicinone is a quinazoline ring-containing alkaloid obtained from the leaves of the plant Adhatoda vasica (Justicia adhatoda) from the family Acanthaceae. Its systematic chemical name is 3-hydroxy-2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-one, and it carries the molecular formula C₁₁H₁₀N₂O₂. The alkaloid, which was named vasicinone upon its first formal isolation, was found to be a much weaker base than its structural precursor vasicine; its molecular weight (by the Rast method) was determined to be approximately 210.

Vasicinone was found to be identical with 2,3-(α-hydroxytrimethylene)-4-quinazolone, which had been prepared earlier by the oxidation of vasicine with 30 per cent hydrogen peroxide. This chemical relationship is pharmacologically significant: vasicinone is reported to be the main metabolite of vasicine, the two being the most biologically active quinazoline alkaloids found in the leaf extracts of Adhatoda vasica.

Racemic vasicinone and (S)-vasicinone are well known for their bronchodilatory activity but also present a broad spectrum of other pharmacological activities such as antitussive, hepatoprotective, anti-inflammatory, antimicrobial, antimycobacterial, and moderate anticancer activities. Acetylcholinesterase (AChE) inhibition and insecticidal activities against the khapra beetle have also been reported.

1.2 Botanical Sources

Vasicinone is primarily sourced from Adhatoda vasica (also known as Justicia adhatoda), a plant belonging to the family Acanthaceae, commonly known as Adosa, Vasaka, or in English, the Malabar nut. It is a perennial shrub found all over India and is commonly known as adulsa or vasaka. The plant grows throughout the Indian peninsula up to an altitude of 1,300 m.

Vasicinone is extracted from the leaves, stem, and roots of Adhatoda vasica. A secondary botanical source also exists: a phytochemical study on the methanol extracts from the seeds of Peganum harmala L. yielded (S)-vasicinone, (R)-vasicinone, and their glucoside derivatives, among other quinazoline alkaloids. Peganum harmala L. (Zygophyllaceae) grows spontaneously in the arid and semiarid areas of North-West China and is also found in North Africa and the Middle East; its seeds and aerial parts have been used as traditional folk medicine to treat various ailments, including cough, asthma, rheumatism, hypertension, diabetes, and jaundice in the Xinjiang Uygur and Mongolian Autonomous Regions of China. This plant is also a well-known and effective herbal medicine in Turkey, Iran, Algeria, and Morocco.

1.3 Co-occurring Phytochemical Constituents

The most abundant and most studied constituents of Adhatoda vasica are pyrroloquinazoline alkaloids, mainly represented by vasicine, vasicinone, vasicoline, vasicinol, and adhatodine. In addition to vasicine, the leaves also contain betaine, steroids, alkanes, kaempferol, quercetin, and additional alkaloids (including vasicinone, adhatodine, vasicinol, adhvasinone, anisotine, adhatonine, and hydroxypeganine). Among other constituents, flavonoids such as apigenin, astragalin, kaempferol, quercetin, and vitexin, and triterpenes like α-amyrin and taraxerone have been reported in the aerial parts.

1.4 Common Forms and Preparations

A number of parts of the plant are commonly used in the forms of decoctions or powders; the juice from the leaves is also frequently used. Vasaka syrup and vasaka liquid extract are mentioned in the Pharmacopoeia of India (The Indian Pharmacopoeia, 1955). Many herbal preparations containing Adhatoda vasica are commercially used, such as Kada in India, Salus Tuss in Germany, and Kan Jang and Spirote in Sweden.

In research and analytical contexts, vasicinone is isolated as a pure compound from plant material through solvent extraction and column chromatography, characterized by techniques including TLC, UV spectroscopy, FT-IR, and ¹H NMR. In some experimental studies, vasicinone (VAO) has been synthesized from vasicine (VAS) via oxidation with hydrogen peroxide.

2. Traditional and Historical Use

2.1 Ayurvedic and Indian Traditional Medicine

Adhatoda vasica, commonly known as Vasaka in Ayurveda, belongs to the family Acanthaceae and has been used in the indigenous system of medicine in India for over 2,000 years. The plant has been used in the indigenous system of medicine in India for approximately 2,500 years and is a well-known plant as a drug in Ayurvedic and Unani medicines.

Vasaka has a long history in traditional medicine, particularly in Ayurveda, where it is categorized as a renewing herb, or Rasayana. Vasaka is the Sanskrit name for the plant, meaning "remover of bodily toxins," which reflects its Ayurvedic role. Adhatoda vasica (also called Vasaka) was used traditionally for the relief of cough, asthma, nasal congestion, bronchial inflammation, upper respiratory infections, bleeding disorders, skin diseases, leprosy, tuberculosis, diabetes, allergic conditions, rheumatism, tumor, and many more diseases.

The leaves, roots, flowers, and bark of this plant have been used for cough, colds, asthma, to liquefy sputum, as a bronchodilator, for bronchial catarrh, bronchitis, and tuberculosis. Traditionally, it was used to treat cough, asthma, phlegm, and bleeding hemorrhoids for both adults and youth, and the plant was recognized to possess antiarthritis, antiseptic, antimicrobial, anti-tuberculosis, anti-inflammatory, and abortifacient properties.

2.2 Unani and Other South Asian Traditions

The plant is also referred to by the Sanskrit name Vasaka and the popular name Malabar nut tree. For more than two millennia, the herb has been utilized in India's traditional medical system. In Ayurvedic and Unani medicine, it is a well-known medication. In Unani medicine, Adhatoda vasica — known as Adosa — was employed for similar respiratory and inflammatory conditions to those in Ayurveda, including as an expectorant and antispasmodic agent. The use of A. vasica as an expectorant and antispasmodic agent was described and an alkaloid with a bitter taste was identified and named 'vasicine' as early as 1890 by Dymock and colleagues.

2.3 Traditional Use in Chinese and Middle Eastern Medicine

Peganum harmala — a secondary source of vasicinone — and its aerial parts have been commonly used as traditional folk medicine to treat various ailments including cough, asthma, rheumatism, hypertension, diabetes, and jaundice in the Xinjiang Uygur and Mongolian Autonomous Regions of China. This plant is also a well-known and effective herbal medicine in Turkey, Iran, Algeria, and Morocco.

2.4 Traditional Use in Reproductive Medicine

Within traditional Indian medicine, Adhatoda vasica was also documented for applications relating to reproductive health. Adhatoda vasica has abortifacient and uterotonic properties, which in traditional contexts made it useful for inducing abortion and for stimulating uterine contractions in order to speed childbirth. This traditional use has been the subject of modern scientific scrutiny (see Safety section below).

3. Active Compounds and Mechanisms of Action

3.1 Structural Class and Chemical Properties

Vasicinone belongs to the pyrroloquinazoline (or quinazoline) class of alkaloids. Alkaloids present in Adhatoda vasica are in the form of pyrrolo-quinazoline derivatives, including vasicine, vasicinone, vasicinol, adhatodine, adhatodinine, adhavasinone, and anisotine. Its molecular formula of C₁₁H₁₀N₂O₂ and the presence of a fused tricyclic ring system — incorporating a pyrroline ring, a pyrrolidine ring, and a quinazolone — distinguish vasicinone from its metabolic precursor vasicine by the presence of an additional ketone group in lieu of a hydroxyl, resulting from oxidation at the C-3 position.

3.2 Respiratory System: Bronchodilatory Mechanisms

The alkaloids vasicinone and vasicine have potent bronchodilator and antiallergic activity; owing to these activities, Adhatoda vasica is effective in acute asthma conditions.

The precise molecular mechanism of vasicinone's bronchodilatory action has been a subject of research. The bronchodilating activity of vasicine has been demonstrated both in vitro and in vivo, while vasicinone, the principal metabolite of vasicine, has shown bronchodilating activity in vitro, but bronchoconstricting activity in vivo. This in vivo complexity is important: both alkaloids in combination (1:1) showed pronounced bronchodilatory activity in vivo and in vitro, and both alkaloids are respiratory stimulants. Vasicine has a cardiac-depressant effect, while vasicinone is a weak cardiac stimulant; the combined effect can be normalized by combining the alkaloids.

Computational research has begun to clarify receptor-level interactions. Vasicine has shown favourable binding affinities for β₂-adrenergic, M3 muscarinic, and oxytocin receptors, according to molecular docking studies. These findings suggest mechanistic parallels with established bronchodilator pharmacology, though direct receptor binding studies specific to vasicinone at the same level of depth remain limited in the published literature.

Bronchodilation tests showed that vasicine (VAS), vasicinone (VAO), and deoxyvasicine (DVAS) prolonged the pre-convulsive time for 28.59%, 57.21%, and 29.66% respectively at a dose of 45 mg/kg in guinea pigs, whereas the reference compound aminophylline prolonged the pre-convulsive time by 46.98% compared with pretreatment. Notably, vasicinone showed the greatest bronchodilatory efficacy among the three alkaloids in this model.

3.3 Anti-inflammatory Mechanisms

Pyrroloquinazoline alkaloids of J. adhatoda such as vasicine and vasicinone have been previously associated with the biological and medicinal properties of this natural product, especially those on inflammation. The alkaloid fraction exercises anti-inflammatory activity by deciphering the regulation of protein expression of some pro-inflammatory cytokines, mRNA downregulation, and NO production inhibition.

In silico studies have demonstrated inhibitory properties of vasicinone on COX-1 and of vasicine on COX-2. The inhibition of cyclooxygenase enzymes represents a classical anti-inflammatory mechanism consistent with reduced prostaglandin synthesis. The NF-κB and AP-1 transcription factor pathways, which are well-established central regulators of inflammatory gene expression, have been implicated in the anti-inflammatory activity of J. adhatoda extracts containing vasicinone.

3.4 Antitussive and Expectorant Mechanisms

Adhatoda vasica has been shown for its antitussive activity as effective as codeine in irritant aerosol and citric acid-induced cough models. Quinazoline alkaloids vasicine (VAS), vasicinone (VAO), and deoxyvasicine (DVAS) have been demonstrated to have significant antitussive, expectorant, and bronchodilating activities.

3.5 Hepatoprotective Mechanisms

Vasicinone isolated from leaves of J. adhatoda was evaluated for hepatoprotective activity using a CCl₄-induced acute hepatotoxicity model in mice. CCl₄ treatments led to significant increases in SGOT, SGPT, and ALP levels; pre-treatment with vasicinone and silymarin (25 mg/kg/day for 7 days) significantly decreased these enzyme levels. Histopathology of the livers from vasicinone and silymarin pre-treated animals showed normal hepatic cords and absence of necrotic changes, suggesting pronounced recovery from CCl₄-induced liver damage.

3.6 Anticancer / Antiproliferative Mechanisms

In an investigation of vasicinone's anti-proliferative effect against A549 lung carcinoma cells, cells treated with various doses of vasicinone (10, 30, 50, and 70 µM) for 72 hours showed a significant decrease in cell viability. Vasicinone treatment also showed DNA fragmentation, LDH leakage, and disruption of mitochondrial potential, and lower wound healing ability in A549 cells. Annexin V/PI staining showed disrupted plasma membrane integrity and permeability. Moreover, vasicinone treatment led to downregulation of Bcl-2 and Fas death receptor, and upregulation of PARP, BAD, and cytochrome c, suggesting that vasicinone mediates apoptosis through both Fas death receptors and Bcl-2-regulated signaling.

3.7 Acetylcholinesterase Inhibition

Among its other pharmacological properties, vasicinone has demonstrated anti-cholinesterase activity. Acetylcholinesterase (AChE) inhibition by vasicinone has been documented in the scientific literature. This mechanism is relevant to neuroprotection and is being studied in the context of Alzheimer's disease research.

4. Scientific Evidence by Area of Use

4.1 Respiratory System: Bronchodilation, Antitussive, and Expectorant Effects

In vitro and animal evidence: An essential oil extracted from the leaves of Adhatoda vasica showed a relaxant effect on the airway smooth muscle in the isolated guinea pig tracheal chain. The relaxant effects of macerated and Soxhlet-obtained aqueous extracts of A. vasica on tracheal smooth muscles of guinea pigs were evaluated, and results indicated that A. vasica has a potent relaxant effect on the tracheal smooth muscles of guinea pigs, which was weaker than that of theophylline.

A study evaluated the antitussive, expectorant, and bronchodilating effects of the quinazoline alkaloids (±)-vasicine, deoxyvasicine (both isolated from the alkaloid fraction of Peganum harmala aerial parts), and (±)-vasicinone (synthesized from vasicine); the three quinazoline alkaloids were tested as antitussives on cough models in mice and guinea pigs. Vasicine, vasicinone, and deoxyvasicine were orally administered at dosages of 5, 15, and 45 mg/kg; cough in these models was induced by ammonia, capsaicin, and citric acid.

A methanolic extract from the whole plant showed antiallergic and antiasthmatic properties in the guinea pig.

Clinical evidence: Numerous in vitro, in vivo, and clinical studies have acknowledged Adhatoda vasica as an important natural agent for many medical illnesses. However, most published clinical data pertains to whole-plant extracts or formulations rather than to isolated vasicinone specifically. A clinical trial was conducted with the vasicine derivative bromhexine (bisolvon) with 30 patients (20 days, 8 mg, three times a day) suffering from a variety of respiratory complaints. Bromhexine (a synthetic derivative of vasicine) is well-established in clinical practice, but this does not constitute direct clinical evidence for vasicinone itself. The evidence base for isolated vasicinone in human respiratory disease remains in vitro and animal-level.

Evidence strength: The bronchodilatory and antitussive evidence for vasicinone, while mechanistically credible and reproduced in multiple animal models, is predominantly preclinical. No published randomized controlled human trials using isolated vasicinone are currently available in the indexed literature.

4.2 Anti-inflammatory Activity

In vitro and animal evidence: A study characterized the most bioactive phytochemicals in A. vasica, including vasicinone, for anti-inflammatory and antimicrobial activities; the anti-inflammatory activity was tested using carrageenan and CFA-model induced paw oedema. The observed results revealed that vasicine showed the most potent anti-inflammatory effects (59.51%) at the dose of 20.0 mg/kg at 6 hours after carrageenan injection, while the maximum inhibition rate was observed for vasicinone (63.94%) at the dose of 10.0 mg/kg at 4 days after CFA injection.

Vasicinone showed potent anti-inflammatory effects in rats after complete Freund's adjuvant injection. In silico, vasicinone has demonstrated inhibitory properties on COX-1.

Evidence strength: Anti-inflammatory evidence for vasicinone is currently confined to in vitro cell studies, in silico molecular docking, and rodent models. No human clinical trials on vasicinone as an isolated compound for inflammatory conditions have been published to date.

4.3 Antimicrobial and Antimycobacterial Activity

Compounds from Adhatoda vasica have shown biological activities including antiseptic, anti-asthmatic, diuretic, antispasmodic, antipyretic, diaphoretic, analgesic, sedative, and fungicidal activities. Vasicinone has been reported to have antimicrobial and antimycobacterial activity.

The antimicrobial activity of isolated vasicinone and related compounds was assessed using the microdilution method. Another pharmacological property relevant to treating respiratory pathologies is the antibacterial activity of these alkaloids.

Evidence strength: Antimicrobial activity for vasicinone has been demonstrated in vitro. The evidence is preliminary, and no clinical antimicrobial studies using isolated vasicinone have been published.

4.4 Hepatoprotective Activity

Leaves of Justicia adhatoda have long been used in the Indian Ayurvedic system of medicine as antitussive, and their crude extract has been previously reported to have hepatoprotective activity. Vasicinone was isolated from leaves of J. adhatoda, column purified and characterized using TLC UV, FT-IR, and ¹H NMR, and then evaluated for hepatoprotective activity using a CCl₄-induced acute hepatotoxicity model in mice.

CCl₄ treatments led to significant increases in SGOT, SGPT, and ALP levels; pre-treatment with vasicinone and silymarin (25 mg/kg/day for 7 days) significantly decreased these enzyme levels. Histopathology showed normal hepatic cords and absence of necrotic changes in vasicinone pre-treated animals, suggesting pronounced recovery. Based on these results, the authors concluded that vasicinone may act as hepatoprotective in mice and that the finding warrants further investigation in human volunteers.

Evidence strength: Hepatoprotective evidence for vasicinone is limited to a single in vivo mouse study using a toxicological model. No human data exist. The evidence is preliminary.

4.5 Anticancer / Antiproliferative Activity

Vasicinone, a quinazoline alkaloid from Adhatoda vasica, is well known for its bronchodilator activity; however, its antiproliferative activities had not been fully elucidated. One study investigated the anti-proliferative effect of vasicinone and its underlying mechanism against A549 lung carcinoma cells.

The A549 cells upon treatment with various doses of vasicinone (10, 30, 50, and 70 µM) for 72 hours showed a significant decrease in cell viability. Vasicinone treatment also showed DNA fragmentation, LDH leakage, and disruption of mitochondrial potential, and lower wound healing ability in A549 cells.

Results indicate that vasicinone and related compounds have significant anticancer activities in vitro on both MCF-7 (human breast adenocarcinoma) and A549 (human lung carcinoma) cancer cells in a concentration-dependent manner, although they showed less cytotoxicity on human red blood cells.

Vasicinone treatment led to downregulation of Bcl-2 and Fas death receptor, and upregulation of PARP, BAD, and cytochrome c, suggesting that the antiproliferative nature of vasicinone mediates apoptosis through both Fas death receptors and Bcl-2-regulated signaling.

It has also been reported that synthesized vasicinone analogues possess apoptotic properties in a cell-specific manner.

Evidence strength: All anticancer evidence for vasicinone is in vitro, derived from cancer cell line experiments. No animal tumor models or human clinical trials have been published for isolated vasicinone. This area is at an early exploratory stage, and the findings do not support any clinical claims.

4.6 Acetylcholinesterase Inhibition and Neuroprotection

Vasicine was found to have a possible anti-inflammatory property in carrageenan-induced inflammation, as well as neuroprotective efficacy in in vitro experiments on neuroblastoma cells by blocking cholinesterases, with implications for Alzheimer's disease and improving memory and cognition. Vasicinone has been noted for anti-cholinesterase activity among its pharmacological profile.

Evidence strength: AChE inhibition by vasicinone is based on in vitro and in silico data. This is a highly preliminary area of investigation with no clinical data in humans.

5. Body Systems and Health Areas

Based on the accumulated preclinical and limited clinical evidence, vasicinone (primarily as a component of Adhatoda vasica) has been associated with the following body systems:

Respiratory system: Adhatoda vasica has an anti-inflammatory action on the respiratory tract and is effective in respiratory tract infection; vasicinone and vasicine have potent bronchodilator and antiallergic activity.
Musculoskeletal and immune systems (inflammation): Vasicinone at the dosage of 10.0 mg/kg in a CFA-induced model exhibited a maximum inhibition rate of 63.94% in rodent anti-inflammatory testing.
Hepatic system: Alkaloids of Adhatoda vasica have also been shown to have significant hepatoprotective effect on liver damage induced by d-galactosamine in rats.
Cardiovascular system: Vasicinone is a weak cardiac stimulant, in contrast to vasicine which has a cardiac-depressant effect; the two effects can be normalized by combining the alkaloids.
Reproductive system: The parent plant is associated with uterotonic and abortifacient effects that are primarily attributable to vasicine (see Safety section), though vasicinone co-occurs in preparations from this plant.
Nervous system: Acetylcholinesterase (AChE) inhibition by vasicinone has been reported, with implications for neurological research.
Oncology (experimental): Vasicinone treatment showed potential free radical scavenging activity and lowered ROS levels in A549 cells; combining these results, vasicinone may be used to develop a new therapeutic agent against oxidative stress-induced lung cancer.

6. Dosage Forms and Reported Dosages

Vasicinone is not available in isolation as a standardized dietary supplement or pharmaceutical in most jurisdictions. The following dosages and forms are those specifically reported in the cited experimental or traditional literature and should not be construed as recommended human doses.

Bronchodilatory / antitussive rodent studies: Vasicine, vasicinone, and deoxyvasicine were orally administered at dosages of 5, 15, and 45 mg/kg in rodent models; cough was induced by ammonia, capsaicin, and citric acid in these experiments.
Anti-inflammatory rodent studies: A maximum inhibition rate for vasicinone of 63.94% was observed at a dose of 10.0 mg/kg administered 4 days after CFA injection in a rodent paw oedema model.
Hepatoprotective rodent studies: Pre-treatment with vasicinone (25 mg/kg/day for 7 days) significantly decreased CCl₄-elevated liver enzyme levels in mice.
In vitro anticancer studies: A549 cells were treated with various doses of vasicinone (10, 30, 50, and 70 µM) for 72 hours in cell viability experiments.
Traditional / whole-plant forms: A number of parts of the plant are commonly used in the forms of decoctions or powders; the juice from the leaves is also frequently used. Vasaka syrup and vasaka liquid extract appear in the Indian Pharmacopoeia (1955), though these specify standardization for total alkaloid content rather than isolated vasicinone.

Adhatoda vasica research reveals limitations that prevent its wider utilization, including insufficient clinical studies, non-standardized dosages, uncertain molecular mechanisms, challenges with bioavailability, and bitter taste. No consensus dosage for isolated vasicinone in human supplementation has been established in the reviewed literature.

7. Safety Considerations and Interactions

7.1 Uterotonic and Abortifacient Concerns

The most well-documented safety concern for preparations containing vasicine and vasicinone from Adhatoda vasica is their uterotonic and abortifacient potential. Adhatoda vasica has abortifacient and uterotonic properties, making it relevant for stimulating uterine contractions; studies on human subjects have shown that the alkaloid vasicine has significant uterotonic activity.

Both in vitro and in vivo studies on the possible abortifacient activity of J. adhatoda have been investigated with rats, guinea pigs, hamsters, rabbits, and human myometrial strips. An investigation was carried out on human volunteers with intravenous injection of vasicine; the results indicated that the uterus became firm and contracted after vasicine treatment, indicating its effectiveness as an oxytocic.

Animal model studies using rats, hamsters, rabbits, and guinea pigs revealed vasicine operates similarly to oxytocin and ergometrine in animal models. The potential of vasicine as a uterotonic and abortifacient is probably due to the synthesis and release of prostaglandins (PG); the dosage and the action are dependent on the stage of pregnancy.

Importantly, the evidence on this point is not uniform across species or routes of administration. One study evaluated the possible abortive effect of an extract of Adhatoda vasica leaf administered orally in rats; the principal alkaloid detected in the extract was vasicine (0.85 ± 0.03%). The extract (325 mg/kg/day) was administered with a gastric cannula to pregnant females between day 1 and 9 of pregnancy, and it was concluded that oral administration of Adhatoda vasica did not produce abortion in any of the treated groups.

The abortifacient effect was observed in guinea pigs depending on the stage of pregnancy and prior estradiol priming. In rats it did not show any abortifacient effect. The abortifacient effect of vasicine, like its uterotonic effect, was more marked under the priming influence of estrogens, which are known to enhance prostaglandin synthesis, indicating that the action of vasicine was mediated through prostaglandin release.

During the last two decades, several scientific reports on oxytocic and abortifacient effects of vasicine and alkaloids derived from the plant have appeared, which leads to questions concerning the safety of A. vasica as a herbal medicine; the major data on traditional uses as well as ethnopharmacological and toxicological studies have been reviewed and evaluated from the point of view of correctness, reliability, relevance, and importance for the overall safety evaluation of A. vasica.

7.2 Overall Safety Data and Tolerability

Based on a critical review, it was concluded that there is not sufficient scientifically strong evidence to explain that A. vasica extract could be harmful to human beings, especially in pregnant women. Major data on traditional uses as well as toxicological studies were evaluated for various measures of correctness, relevance, importance, and reliability for the overall evaluation of A. vasica safety.

7.3 Cardiovascular Considerations

Vasicinone is a weak cardiac stimulant, while vasicine has a cardiac-depressant effect. These opposing cardiovascular effects of the two alkaloids are typically encountered together in whole-plant preparations and standardized extracts.

7.4 Drug Derivative Relationship

A clinically important connection exists between vasicinone's parent compound vasicine and the pharmaceutical drug bromhexine. One of the synthetic derivatives of vasicine is bromhexine (bisolvon; N-cyclo-N-methyl-(2-amino-3,5-dibromo-benzyl)amine hydrochloride), which has been reported to possess mucus liquefying and expectorant activity. This relationship illustrates both the pharmacological relevance of the vasicine/vasicinone scaffold and the rationale for ongoing interest in the parent alkaloids and their derivatives.

7.5 Limitations and Research Gaps

Adhatoda vasica research reveals limitations including insufficient clinical studies, non-standardized dosages, uncertain molecular mechanisms, challenges with bioavailability, bitter taste, and toxicity concerns. Resolving these gaps with more thorough clinical trials, better formulations, and regulatory compliance will increase its medicinal potential and economic viability.

Though most studies have been performed based on leaf extracts, the seasonal variation of alkaloids may limit the efficiency and reproducibility of these studies. The specific contribution of vasicinone versus vasicine versus whole-extract synergism remains incompletely resolved in the scientific literature.

References

Condiciones de Salud

Condiciones de salud que Vasicinona puede ayudar a apoyar.

AlcalosisCientífico
Vasicinone is the principal metabolite of vasicine from Adhatoda vasica, demonstrating bronchodilating activity in vitro and contributing to the plant's established bronchial pharmacology. It and vasicine together define the bronchospasmolytic profile of Adhatoda vasica preparations used in Ayurvedic bronchitis and asthma treatment. The semi-synthetic mucolytic ambroxol, derived from vasicine/vasicinone chemistry, has extensively documented clinical use in bronchitis.
EndometriosisCientífico
Vasicinone is the principal metabolite of vasicine from Adhatoda vasica with demonstrated in vitro bronchodilatory activity. It is documented alongside vasicine as a therapeutic agent for bronchitis in patent literature (US Patent 11351213). It is also a recognized pharmacologically active compound in Ayurvedic Vasaka preparations listed in the Indian Pharmacopoeia.
Manos y Pies FríosCientífico
Vasicinone is a quinazoline alkaloid from Adhatoda vasica that shows synergistic bronchodilatory and expectorant effects with vasicine. Studies indicate it enhances vasicine's therapeutic efficacy in respiratory applications, contributing to increased bronchial secretion and mucus clearance. Preclinical evidence supports its role in the combined expectorant activity of Adhatoda vasica.

Sistemas Corporales

Sistemas corporales que Vasicinona puede ayudar a apoyar.

No hay sistemas corporales disponibles.